Martin L Moore
Overview
Explore the profile of Martin L Moore including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
94
Citations
3309
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sibert B, Kim J, Yang J, Ke Z, Stobart C, Moore M, et al.
Nat Commun
. 2024 Jul;
15(1):5923.
PMID: 39004634
Respiratory syncytial virus (RSV) is an enveloped, filamentous, negative-strand RNA virus that causes significant respiratory illness worldwide. RSV vaccines are available, however there is still significant need for research to...
2.
Roe M, Perez M, Hsiao H, Lapp S, Sun H, Jadhao S, et al.
J Infect Dis
. 2022 Oct;
227(1):50-60.
PMID: 36281651
Background: Respiratory syncytial virus (RSV) is a leading viral respiratory pathogen in infants. The objective of this study was to generate RSV live-attenuated vaccine (LAV) candidates by removing the G-protein...
3.
Tioni M, Jordan R, Pena A, Garg A, Wu D, Phan S, et al.
NPJ Vaccines
. 2022 Jul;
7(1):85.
PMID: 35906244
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the COVID-19 global pandemic. SARS-CoV-2 is an enveloped RNA virus that relies on its trimeric surface glycoprotein spike...
4.
Human S, Hotard A, Rostad C, Lee S, McCormick L, Larkin E, et al.
J Virol
. 2020 Oct;
95(2).
PMID: 33115881
This study identified a genotype of respiratory syncytial virus (RSV) associated with increased acute respiratory disease severity in a cohort of previously healthy term infants. The genotype (2stop+A4G) consists of...
5.
Frey S, Varner C, Arsiwala A, Currier M, Moore M, Kane R
Adv Healthc Mater
. 2020 Aug;
10(4):e2000714.
PMID: 32755047
Respiratory syncytial virus (RSV), for which there is currently no licensed vaccine, displays a fusion (F) protein that is considered a vaccine target. This protein has an antigenic site called...
6.
Kwon Y, Lee Y, Kim K, Jung Y, Li Z, Jeeva S, et al.
Vaccine
. 2019 Sep;
37(44):6656-6664.
PMID: 31542260
Pre-fusion stabilizing mutations (DS-Cav1) in soluble fusion (F) proteins of human respiratory syncytial virus (RSV) were previously reported. Here we investigated the antigenic and immunogenic properties of pre-fusion like RSV...
7.
Kwon Y, Hwang H, Lee Y, Kim K, Lee Y, Kim M, et al.
Immune Netw
. 2019 Jul;
19(3):e18.
PMID: 31281715
Formalin-inactivated respiratory syncytial virus (RSV) vaccination causes vaccine-enhanced disease (VED) after RSV infection. It is considered that vaccine platforms enabling endogenous synthesis of RSV immunogens would induce favorable immune responses...
8.
DeFord D, Nosek J, Castiglia K, Hasik E, Franke M, Nick B, et al.
J Gen Virol
. 2019 Jun;
100(7):1112-1122.
PMID: 31184573
Respiratory syncytial virus (RSV) remains a leading cause of infant mortality worldwide and exhaustive international efforts are underway to develop a vaccine. However, vaccine development has been hindered by a...
9.
Turi K, Romick-Rosendale L, Gebretsadik T, Watanabe M, Brunwasser S, Anderson L, et al.
Metabolomics
. 2019 Mar;
14(10):135.
PMID: 30830453
Background: Respiratory syncytial virus (RSV) infection in infants causes significant morbidity and is the strongest risk factor associated with asthma. Metabolites, which reflect the interactions between host cell and virus,...
10.
Ke Z, Dillard R, Chirkova T, Leon F, Stobart C, Hampton C, et al.
Viruses
. 2018 Aug;
10(8).
PMID: 30127286
Human respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract disease in young children. With repeat infections throughout life, it can also cause substantial disease in the...